Jordan Elm to Disease Progression
This is a "connection" page, showing publications Jordan Elm has written about Disease Progression.
Connection Strength
0.483
-
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
Score: 0.109
-
Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. J Parkinsons Dis. 2015; 5(4):731-6.
Score: 0.095
-
Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort. J Parkinsons Dis. 2015; 5(4):773-82.
Score: 0.095
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.048
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.048
-
Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143.
Score: 0.028
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.024
-
Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis. 2013 Aug; 22(6):742-9.
Score: 0.019
-
The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
Score: 0.016